Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV sildenafil in neonates with PPHN or hypoxic respiratory failure at risk for PPHN
2014-004166-23Phase 2
- Sponsor
- Pfizer
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sildenafil in persistent pulmonary hypertension of the newborn (PPHN) (3 arms), sponsored by Pfizer. Primary endpoint: Plasma concentration of sildenafil and UK-103320 population pharmacokinetics.
02
Drugs
sildenafil
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on 2014-004166-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004166-23.